Exploring Long-term Pain Relief with 5% Dextrose Added to Local Anesthetic
Unknown statusNot applicableNCT06617065
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
Brief summary (from the registry)
The goal of this single-arm, non-randomized, open-label trial is to determine whether adding a 5% dextrose solution to a local anesthetic can improve outcomes in patients with chronic non-cancer pain. The main question we aim to answer is whether adding a low-concentration (5%) dextrose solution to local anesthetics increases the effectiveness of trigger point injections and/or peripheral nerve blockade in the treatment of chronic non-cancer pain. Researchers will compare the outcomes of adding 5% dextrose to the usual local anesthetic solution with the outcomes of using the local anesthetic alone to determine if injection therapy is more effective when dextrose is added. Participants will: * Attend their scheduled injection treatments every two (2) weeks for a total of six (6) visits. * Complete a demographic form at the first visit, and the usual pre-visit questionnaires (the Waiting Room Form and the Brief Pain Inventory (BPI)) at every visit, as well as four (4) weeks after the sixth visit (approximately 16 weeks from the study start date). They will also need to complete two short questionnaires-the Patient Health Questionnaire (PHQ-9) and the Patient Global Impression of Change (PGIC)-at the specified intervals. * Complete all forms, which will be securely emailed to them.
Study details
- Official title
- A Prospective, Open-label Self-controlled Trial to Assess Long-term Changes in Pain and Function with Addition of 5% Dextrose to Local Anesthetic Solutions - the PALPADE Study
- Conditions
- Chronic Non-cancer Pain
- Interventions
- Drug: Addition of 1 mL of 50% dextrose solution to the usual local anesthetic solution of choice for each patient.
- Sponsor
- The Seekers Centre
- Start date
- 2024-09-03
- Primary completion
- 2025-01-30
- Sex
- All
- Age range
- from 18 Years
- Results posted
- No results posted in this snapshot
- Countries
- Canada
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: 1. Men and women ≥ 18 years old, inclusive. 2. A primary diagnosis of chronic non-cancer pain as determined by their physician. 3. Present chronic pain symptoms of at least 3 months in duration. 4. Currently receiving injection therapy every 1-3 weeks for at least 6 months. 5. English proficiency Exclusion Criteria: 1. Age less than 18 years 2. Scar or infection at the blockade puncture site 3. Pregnancy 4. Unstable neurologic or psychiatric diagnosis, including schizophrenia, bipolar disorder, substance use disorder, depression or anxiety, dementia or neurodegenerative disorder 5. Serious acute life stressor, clinical illness, or organ disease within the past three months 6. Serious or significant traumatic injury, surgical or dental procedure within the past three months 7. Lack of English proficiency or unable to complete patient forms 8. Denial or withdrawal of consent, as per the informed consent form (ICF).
Canadian sites (1)
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT06617065